| scholarly article | Q13442814 |
| P50 | author | Sally Temraz | Q82743212 |
| P2093 | author name string | Ali Shamseddine | |
| Deborah Mukherji | |||
| P2860 | cites work | Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055). | Q53390153 |
| Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9. | Q54314770 | ||
| The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer | Q54535188 | ||
| A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens | Q82758717 | ||
| PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. | Q36661711 | ||
| Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. | Q37349748 | ||
| Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. | Q37596249 | ||
| Sequencing of treatment in metastatic colorectal cancer: where to fit the target | Q37602729 | ||
| Resistance to MEK Inhibitors: Should We Co-Target Upstream? | Q37859182 | ||
| PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types | Q38084846 | ||
| Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies | Q38175833 | ||
| Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials | Q38239192 | ||
| Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer | Q38445646 | ||
| Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer | Q39140763 | ||
| MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors | Q39355055 | ||
| The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition | Q39380338 | ||
| Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas | Q39384830 | ||
| Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition | Q39442875 | ||
| Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. | Q39568646 | ||
| Discovery of novel insulin-like growth factor-1 receptor inhibitors with unique time-dependent binding kinetics | Q39780387 | ||
| Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines | Q39819940 | ||
| PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers | Q39859169 | ||
| Combined inhibition of MEK and mTOR signaling inhibits initiation and progression of colorectal cancer | Q39887307 | ||
| Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy | Q40039847 | ||
| AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 | ||
| Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer | Q41503593 | ||
| Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer | Q42085487 | ||
| Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells | Q42437883 | ||
| The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer | Q43152544 | ||
| AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis | Q43833515 | ||
| Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies | Q46595207 | ||
| Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex | Q24295120 | ||
| Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling | Q24323370 | ||
| Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer | Q27324821 | ||
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 | ||
| KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. | Q27851616 | ||
| Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212 | Q27851693 | ||
| Mammalian MAP kinase signalling cascades | Q28204140 | ||
| Phosphorylation of the MAP Kinase ERK2 Promotes Its Homodimerization and Nuclear Translocation | Q28609161 | ||
| mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 | ||
| BRAF mutation predicts sensitivity to MEK inhibition | Q29614281 | ||
| Molecular mechanisms of mTOR-mediated translational control | Q29615529 | ||
| PI3K pathway alterations in cancer: variations on a theme | Q29615530 | ||
| From basic research to clinical development of MEK1/2 inhibitors for cancer therapy | Q33698374 | ||
| Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. | Q33927952 | ||
| Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells | Q34188530 | ||
| The insulin-like growth factor system and cancer | Q34200058 | ||
| A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. | Q34768386 | ||
| PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors | Q34769343 | ||
| The PTEN-PI3K pathway: of feedbacks and cross-talks | Q34828662 | ||
| PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling | Q35227481 | ||
| KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis | Q35231369 | ||
| A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours | Q35677661 | ||
| The preclinical evaluation of the dual mTORC1/2 inhibitor INK-128 as a potential anti-colorectal cancer agent | Q36215450 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | mitogen-activated protein kinase kinases | Q6593810 |
| phosphoinositide-3 kinase inhibitor | Q7187512 | ||
| protein kinase inhibitors | Q7251487 | ||
| signal transduction | Q828130 | ||
| colorectal neoplasm | Q58833976 | ||
| proto-oncogene proteins p21(ras) | Q78316242 | ||
| B-Raf proto-oncogene, serine/threonine kinase | Q21109218 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 22976-22988 | |
| P577 | publication date | 2015-09-23 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers | |
| P478 | volume | 16 |
| Q37725589 | ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer. |
| Q89441275 | Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations |
| Q55332287 | Alterations of mTOR signaling impact metabolic stress resistance in colorectal carcinomas with BRAF and KRAS mutations. |
| Q90382919 | Autophagy Function and Dysfunction: Potential Drugs as Anti-Cancer Therapy |
| Q53705974 | BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers. |
| Q35962621 | BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis |
| Q42705608 | Combination of mTOR and MAPK Inhibitors-A Potential Way to Treat Renal Cell Carcinoma |
| Q97542726 | Combined targeting of PI3K and MEK effector pathways via CED for DIPG therapy |
| Q64057563 | DPS-2: A Novel Dual MEK/ERK and PI3K/AKT Pathway Inhibitor with Powerful Ex Vivo and In Vivo Anticancer Properties |
| Q90643598 | Defining subpopulations of differential drug response to reveal novel target populations |
| Q57167787 | Design, Synthesis and Biological Activity Evaluation of S-Substituted 1-5-Mercapto-1,2,4-Triazole Derivatives as Antiproliferative Agents in Colorectal Cancer |
| Q64980788 | Downregulation of PIK3CA via antibody-esiRNA-complexes suppresses human xenograft tumor growth. |
| Q89796479 | Effects of MIR143 on rat sarcoma signaling networks in solid tumors: A brief overview |
| Q28067118 | Focal Adhesion Kinase-Dependent Role of the Soluble Form of Neurotensin Receptor-3/Sortilin in Colorectal Cancer Cell Dissociation |
| Q52839686 | Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer |
| Q60302891 | HJC0152, a novel STAT3 inhibitor with promising anti-tumor effect in gastric cancer |
| Q36345358 | High-throughput detection of clinically targetable alterations using next-generation sequencing. |
| Q33601377 | In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor |
| Q28076490 | Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer |
| Q52794464 | Molecular Biomarkers for the Evaluation of Colorectal Cancer. |
| Q40341349 | Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. |
| Q64886283 | Molecular biomarkers and precision medicine in colorectal cancer: a systematic review of health economic analyses. |
| Q39007820 | Neomorphic mutations create therapeutic challenges in cancer. |
| Q58801701 | New Multitarget Approaches in the War Against Glioblastoma: A Mini-Perspective |
| Q51744124 | New localization and function of calpain-2 in nucleoli of colorectal cancer cells in ribosomal biogenesis: effect of KRAS status |
| Q88512529 | Ocular Toxicity Profile of ST-162 and ST-168 as Novel Bifunctional MEK/PI3K Inhibitors |
| Q90389869 | Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors |
| Q37544392 | Reduced phosphorylation of ribosomal protein S6 is associated with sensitivity to MEK inhibition in gastric cancer cells |
| Q47648532 | Report and Application of a Tool Compound Data Set. |
| Q94569373 | Sequential Ras/MAPK and PI3K/AKT/mTOR pathways recruitment drives basal extrusion in the prostate-like gland of Drosophila |
| Q47760790 | Structure-Guided Design and Initial Studies of a Bifunctional MEK/PI3K Inhibitor (ST-168). |
| Q36362412 | Suppression subtractive hybridization identified differentially expressed genes in colorectal cancer: microRNA-451a as a novel colorectal cancer-related gene. |
| Q90357648 | Synergistic inhibition of MEK and reciprocal feedback networks for targeted intervention in malignancy |
| Q57490053 | Synthesis and Biological Evaluation of New Madecassic Acid Derivatives Targeting ERK Cascade Signaling |
| Q47100954 | Targeted elimination of senescent Ras-transformed cells by suppression of MEK/ERK pathway |
| Q49417294 | Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine |
| Q92830319 | Targeting β-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations |
| Q89906548 | Tea polyphenols and their chemopreventive and therapeutic effects on colorectal cancer |
| Q33733048 | The identification and validation of Trichosstatin A as a potential inhibitor of colon tumorigenesis and colon cancer stem-like cells |
| Q37165886 | Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer |
| Q64274877 | mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy |
Search more.